The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

• Main Authors: Jing Ni (Author), Xianzhong Cheng (Author), Qian Zhao (Author), Zhiqin Dai (Author), Xia Xu (Author), Wenwen Guo (Author), Hongyuan Gu (Author), Rui Zhou (Author), Yan Wang (Author), Xiaoxiang Chen (Author)
• Format: Book
• Published: BMC, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in BRCAmt patients or platinum-sensitive rec...